New pill combo shows promise for older myeloma patients
NCT ID NCT04998786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants will receive the drugs for up to 6 cycles, with two drugs continued until the disease worsens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ixazomib, iberdomide, and dexamethasone (oral drugs)
What this could lead to
If successful, this could offer a convenient, all-oral treatment option for elderly patients with relapsed multiple myeloma, potentially delaying disease progression.
What could go wrong
This is an early Phase 2 study with only 75 participants, so results may not apply to all patients. The drugs can cause side effects like fatigue, nausea, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA AT FIRST RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Lyon Sud
Lyon, France
-
CH de la cote basque
Bayonne, France
-
CHD les Oudairies
La Roche-sur-Yon, France
-
CHR
Annecy, France
-
CHRU
Dijon, France
-
CHRU
Nancy, France
-
CHRU
Rennes, France
-
CHRU Bretonneau
Tours, France
-
CHRU Hopital Haut Lévêque
Bordeaux, France
-
CHRU Lille
Lille, France
-
CHU
Caen, France
-
CHU
Clermont-Ferrand, France
-
CHU
Limoges, France
-
CHU
Nantes, France
-
CHU
Toulouse, France
-
CHU Henri Mondor
Paris, France
-
Centre hospitalier
Strasbourg, France
-
Hopital St Antoine
Paris, France
-
Hopital de l'archet
Nice, France
-
Hôpital Cochin
Paris, France
-
University Hospital
Poitiers, France